Recombinant Bovine Growth Hormone vs Perfluorinated Compounds (PFAS): which is worse?
Quick answer: Recombinant Bovine Growth Hormone carries the heavier risk profile. Recombinant Bovine Growth Hormone is — in the EU and — in the US; Perfluorinated Compounds (PFAS) is — in the EU and — in the US.
| Property | Recombinant Bovine Growth Hormone | Perfluorinated Compounds (PFAS) |
|---|---|---|
| EU status | — | — |
| US status | — | — |
| Risk level | — | — |
| Banned in | European Union, Canada, Japan, Australia, New Zealand | European Union (broadly restricting PFAS in food contact materials since 2020; EU-wide PFAS restriction proposal under REACH), Denmark (banned PFAS in all food packaging 2020) |
| Restricted in | — | United States (EPA has set maximum contaminant levels for 6 PFAS in drinking water in 2024; FDA has been working with industry to phase out certain PFAS from food packaging) |
| Category | additive | additive |
| Where it hides | — | — |
What is Recombinant Bovine Growth Hormone?
Recombinant bovine growth hormone (rBGH), also called recombinant bovine somatotropin (rBST), is a synthetically produced version of the naturally occurring cattle growth hormone, manufactured using genetically engineered E. coli bacteria. Injected into dairy cows, it increases milk production by 10-15%. It was FDA-approved in 1993 under the brand name Posilac (originally Monsanto, later Elanco).
What is Perfluorinated Compounds (PFAS)?
Per- and polyfluoroalkyl substances (PFAS) are a large family of synthetic chemicals characterized by extremely strong carbon-fluorine bonds. They are used in food packaging (grease-resistant coatings), non-stick cookware (PTFE/Teflon), food processing equipment, firefighting foam, and many industrial applications. The 'forever chemicals' moniker reflects their extreme environmental persistence.
Documented risks
Recombinant Bovine Growth Hormone: The central human health concern is that rBGH treatment significantly elevates insulin-like growth factor 1 (IGF-1) levels in treated cows' milk. IGF-1 is a naturally occurring growth hormone that promotes cell growth and division. Multiple epidemiological studies have associated elevated blood IGF-1 levels with increased cancer risk in humans. A 1998 study in The Lancet (Hankinson et al.) found that women with the highest IGF-1 blood levels had approximately 7 times the breast cancer risk compared to those with the lowest levels. A 2004 meta-analysis in JNCI (the Journal of the National Cancer Institute) confirmed significant associations between high IGF-1 levels and breast, prostate, and colorectal cancer risk. The mechanistic question is whether consuming rBGH-treated milk raises blood IGF-1 levels in humans. The FDA and WHO/FAO Codex Alimentarius concluded that IGF-1 in milk is a protein largely digested in the GI tract before absorption. Canadian regulatory researchers challenged this, arguing that pasteurization reduces proteases that would otherwise break down IGF-1, potentially allowing more intact IGF-1 to survive digestion. The Codex Alimentarius Commission made history in 1999 by declining to endorse rBST safety maximum residue limits — a split vote (33 in favor of the MRL, 29 against, with abstentions) demonstrating fundamental international disagreement. This is one of very few cases where Codex failed to establish a safety standard. Animal welfare is a second major concern: Health Canada's comprehensive 1999 review found that rBGH-treated cows had 25% higher rates of clinical mastitis, 50% higher lameness risk, increased reproductive problems, and shortened productive lifespans, requiring substantially more antibiotic treatment — an antibiotic resistance concern. Canada rejected rBGH approval in 1999 after its scientific review; the EU banned it in 1999.
Perfluorinated Compounds (PFAS): PFAS are among the most extensively studied and harmful groups of synthetic chemicals in the modern environment. Their unique carbon-fluorine bond stability means they do not break down in the environment or in human body tissues — contributing to bioaccumulation over a lifetime. Health effects documented in human epidemiological studies include: - Cancer: PFOA (perfluorooctanoic acid) and PFOS (perfluorooctanesulfonic acid) have been associated with kidney cancer, testicular cancer, thyroid cancer, bladder cancer, and non-Hodgkin lymphoma in occupationally exposed workers and community members with contaminated drinking water. IARC classified PFOA as Group 1 (human carcinogen) in 2023 and PFOS as Group 2B. - Endocrine disruption: PFAS disrupt thyroid hormone signaling and sex hormone balance. Multiple studies find associations between PFAS exposure and hypothyroidism, early puberty in girls, and reduced sperm quality. - Immune suppression: studies have found that PFAS exposure is associated with reduced vaccine response in children and adults, suggesting PFAS may impair immune function. - Developmental effects: prenatal PFAS exposure has been associated with lower birth weight, developmental delays, and reduced immune response in infants. - Cholesterol: PFAS exposure consistently raises LDL cholesterol levels, increasing cardiovascular disease risk. The 2023 EPA MCLG (maximum contaminant level goal) for PFOA and PFOS is zero — reflecting the agency's conclusion that there is no safe level. The EPA set enforceable MCLs in drinking water in 2024. The DuPont/3M PFOA/PFOS contamination of drinking water in communities near Teflon manufacturing facilities led to a $671 million settlement (DuPont/Chemours, 2017) and $10.3 billion 3M settlement (2023) — among the largest environmental contamination settlements in history.
Scan a barcode and we'll flag both Recombinant Bovine Growth Hormone and Perfluorinated Compounds (PFAS) (plus 200+ other ingredients banned overseas).
Scan free →